miR-34a dysregulation has been observed in a wide range of cancers, including breast cancer, lung cancer, colorectal cancer, prostate cancer, and hepatocellular carcinoma. In many of these cancers, miR-34a is downregulated, which contributes to the loss of its tumor-suppressive functions and facilitates cancer progression.
